GlucoSet

Key People

• Nicolas Elvemo - Co-Founder & Chief Executive Officer
• Lukas Scherer - Chief Technology Officer
• Craig Cooper - Board Member
• Jan Sollid - Chairman
• Jrgen Nilsen - Board Member
• Rune Srum - Board Member
• Simon Schweighofer - Deputy Board Member

Assessment

Team

Aspect: First-time 10+ yrs
Summary: The leadership team comprises first-time entrepreneurs with over a decade of experience in the medical device industry.

The leadership team's background suggests a strong foundation in the medical device sector, enhancing the company's potential for success.

Clinical Need

Aspect: Very Strong
Summary: There is a critical need for continuous glucose monitoring in ICU patients to reduce complications and mortality.

The company's focus on continuous glucose monitoring in ICU settings addresses a pressing clinical need, potentially improving patient outcomes and reducing healthcare costs.

Competition

Aspect: First mover
Summary: GlucoSet appears to be among the first to offer intravascular continuous glucose monitoring specifically for ICU patients.

Being an early entrant in this niche market allows GlucoSet to set industry standards and build brand recognition, providing a competitive advantage.

Technical Challenge

Aspect: Complex
Summary: Developing accurate and reliable intravascular sensors for continuous glucose monitoring presents significant technical challenges.

The intricate nature of intravascular sensor technology requires substantial R&D efforts, which could affect time-to-market and resource allocation.

Patent

Aspect: Strong
Summary: GlucoSet holds a portfolio of granted patents related to their sensor technology.

A robust patent portfolio protects the company's innovations, deterring competitors and potentially increasing valuation.

Financing

Aspect: Well-funded
Summary: The company has secured significant funding, including a 6M Series A round led by the Swiss Diabetes Venture Fund.

The substantial funding obtained provides the necessary resources for product development, regulatory processes, and market entry strategies.

Regulatory

Aspect: Running FIH
Summary: GlucoSet is currently conducting First-In-Human (FIH) trials for their intravascular glucose sensor.

While FIH trials are a positive step, the company still faces significant regulatory milestones before achieving market approval.

Opportunity Rollup

Odds of Success

3.85

Peak Market Share

5.75

Segment CAGR

9.5%

Market Segment

Glucose Monitoring

Market Sub Segment

Intravascular Continuous Glucose Monitoring for ICU Patients

Key Takeaway

GlucoSet's innovative intravascular glucose monitoring technology addresses a critical need in ICU settings, supported by a strong team and solid funding, but faces technical and regulatory challenges ahead.